A Phase 1b/2 Open-Label Study of the Efficacy and Safety of Etigilimab (MPH313) Administered in Combination with Nivolumab to Subjects with Locally Advanced or Metastatic Solid Tumors

Administered By

Awarded By

Contributors

Start/End

  • May 27, 2021 - June 14, 2026